Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022
Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
A trend for stabilized or improved visual acuity was observed
Observed adverse events were anticipated based on the mechanism of LBS-008 action
STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
A trend for stabilized or improved visual acuity was observed
Observed adverse events were anticipated based on the mechanism of LBS-008 action
STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
LBS-008(又名替拉貝坦)在青少年Stargardt病(STGD1)受試者中顯示出可接受的安全性
觀察到視力穩定或提高的趨勢
根據LBS-008的作用機制預測觀察到的不良事件
來自1b期研究的STGD1受試者現在正在參與為期2年的2期延期
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧